These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27631464)

  • 1. Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug Interactions.
    Töpper C; Steinbach CL; Dorn C; Kratzer A; Wicha SG; Schleibinger M; Liebchen U; Kees F; Salzberger B; Kees MG
    Ther Drug Monit; 2016 Oct; 38(5):573-8. PubMed ID: 27631464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?
    Pea F; Cojutti PG; Baraldo M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):303-308. PubMed ID: 28419737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors associated with high linezolid trough plasma concentrations.
    Morata L; De la Calle C; Gómez-Cerquera JM; Manzanedo L; Casals G; Brunet M; Cobos-Trigueros N; Martínez JA; Mensa J; Soriano A
    Expert Opin Pharmacother; 2016 Jun; 17(9):1183-7. PubMed ID: 27156708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
    Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.
    Cojutti P; Candoni A; Forghieri F; Isola M; Zannier ME; Bigliardi S; Luppi M; Fanin R; Pea F
    Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):474-9. PubMed ID: 26572687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression Models.
    Srinivas NR; Syed M
    Drugs R D; 2016 Mar; 16(1):69-79. PubMed ID: 26747454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
    Cojutti P; Pai MP; Pea F
    Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study.
    Wicha SG; Frey OR; Roehr AC; Pratschke J; Stockmann M; Alraish R; Wuensch T; Kaffarnik M
    Int J Antimicrob Agents; 2017 Oct; 50(4):557-563. PubMed ID: 28711678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
    Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
    Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Clinical Study in Elderly Patients.
    Bel Kamel A; Bourguignon L; Marcos M; Ducher M; Goutelle S
    Ther Drug Monit; 2017 Feb; 39(1):83-87. PubMed ID: 27861313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains.
    Zhao W; Kong L; Wu C; Wu X
    Eur J Clin Pharmacol; 2021 Jan; 77(1):79-86. PubMed ID: 32812063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of pharmacokinetic target attainment and hematological toxicity of linezolid in pediatric patients.
    Abouelkheir M; Aldawsari MR; Ghonem L; Almomen A; Alsarhani E; Alsubaie S; Alqahtani S; Kurdee Z; Alsultan A
    Eur J Clin Pharmacol; 2024 Nov; 80(11):1807-1817. PubMed ID: 39183194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance.
    Allegra S; Di Paolo A; Cusato J; Fatiguso G; Arrigoni E; Danesi R; Corcione S; DʼAvolio A
    Ther Drug Monit; 2018 Oct; 40(5):602-609. PubMed ID: 29979333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study.
    Zoller M; Maier B; Hornuss C; Neugebauer C; Döbbeler G; Nagel D; Holdt LM; Bruegel M; Weig T; Grabein B; Frey L; Teupser D; Vogeser M; Zander J
    Crit Care; 2014 Jul; 18(4):R148. PubMed ID: 25011656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients.
    Pea F; Viale P; Lugano M; Baccarani U; Pavan F; Tavio M; Adani GL; Della Rocca G; Furlanut M
    J Antimicrob Chemother; 2009 Jan; 63(1):167-9. PubMed ID: 18952619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of linezolid and its major metabolites PNU-142300 and PNU-142586 in adult patients.
    Sakurai N; Kawaguchi H; Abe J; Kuwabara G; Imoto W; Shibata W; Yamada K; Yasui H; Nakamura Y; Kakeya H
    Pharmacotherapy; 2022 Sep; 42(9):707-715. PubMed ID: 35856168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
    Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
    BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.
    Pea F; Furlanut M; Cojutti P; Cristini F; Zamparini E; Franceschi L; Viale P
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4605-10. PubMed ID: 20733043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy.
    Ehmann L; Simon P; Busse D; Petroff D; Dorn C; Huisinga W; Dietrich A; Zeitlinger M; Wrigge H; Kloft C
    Clin Microbiol Infect; 2020 Sep; 26(9):1222-1228. PubMed ID: 32311473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.